Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 44

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 44
---
, based on the closing price of Aptorum’s Class A ordinary shares on September30, 2025, Wainwright would receive warrants to purchase up to 247,525shares of the Combined Company’s common stock. In the event that DiamiR (or the Combined Company) consummates one or more financing transactions, with gross proceeds of at least $4,000,000 following the execution of the Merger Agreement through and including the consummation of the Merger and within 90 days thereafter, Wainwright shall receive a cash fee of $250,000, which cash fee shall be paid in lieu of a number of warrants equal to $250,000 as described in the immediately preceding sentence (and, if previously issued, a number of warrants equal to $250,000 shall be cancelled). In addition, Wainwright shall receive reimbursement of reasonable out -of-pocketexpenses, including legal fees and expenses, incurred by Wainwright in connection with financial advisory agreement. As of October3, 2025, Wainwright has incurred $0 in out -of-pocketexpenses. Dr. Kira Sheinerman, the co -founderof DiamiR, is currently a managing director of Wainwright and shall be appointed to the Combined Company’s board of directors. Aptorum’s Reasons for the Merger Since inception, the Company has sought to maximize shareholder value by licensing and acquiring technologies that have scientific merit and ultimately, meaningful market value after commercialization. We believe great opportunity exists for therapeutic agents developed for CNS indications, including neurodegenerative diseases such as Alzheimer’s and Parkinson’s, as well as certain cancers like glioblastoma and neuroblastoma. Due to the heterogeneity of these diseases, there is a wide spectrum of clinical manifestations and outcomes in patients with these conditions. Therefore, there is a strong need for accurate, minimally invasive biomarkers reflective of pathophysiological processes underlying these diseases that can be used for disease progression and treatment response monitoring. As such, the Company’s management finds great value in DiamiR’s innovation and proprietary technology. DiamiR’s platform technology, which is based on targeted selection and quantitative analysis of organ -enriched, including brain -enriched, microRNA (miRNAs) detectable in blood plasma, has a strong potential to provide molecular diagnostic solutions for risk assessment and monitoring of neuro and other indications in clinical trials, which we believe will enable more effective drug development for these indications. DiamiR’s CLIA/CAP -